Home » OSI PHARMACEUTICALS GRANTS LICENSE TO MERCK
OSI PHARMACEUTICALS GRANTS LICENSE TO MERCK
OSI Pharmaceuticals has announced that its diabetes and obesity business unit (OSI) Prosidion, has granted Merck a worldwide, non-exclusive license under U.S. Patent No. 6,890,898 and foreign equivalents thereof which claim combination therapy comprising administration of a DPIV inhibitor and another therapeutic agent for the treatment of Type 2 diabetes and related indications. OSI will receive upfront, milestone and royalty payments. Additional financial terms were not disclosed.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May